CDKN2A and central nervous system cancer: In our study, the calibration curve reflected a high degree of agreement between the predictions of the model in the training and validation sets and the actual status, indicating that the model displayed good performance and reliability in predicting CDKN2A/B homozygous deletion in gliomas (Figure 4).